Literature DB >> 34238640

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer.

Stefano Partelli1, Francesco Sclafani2, Sorin Traian Barbu3, Marc Beishon4, Pierluigi Bonomo5, Graça Braz6, Filippo de Braud7, Thomas Brunner8, Giulia Martina Cavestro9, Mirjam Crul10, Maria Die Trill11, Piero Ferollà12, Ken Herrmann13, Eva Karamitopoulou14, Cindy Neuzillet15, Franco Orsi16, Hanna Seppänen17, Martina Torchio7, Danila Valenti18, Giulia Zamboni19, Marc Zins20, Alberto Costa21, Philip Poortmans22.   

Abstract

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give patients, health professionals, managers and policymakers a guide to essential care throughout the patient journey. Pancreatic cancer is an increasing cause of cancer mortality and has wide variation in treatment and care in Europe. It is a major healthcare burden and has complex diagnosis and treatment challenges. Care must be carried out only in pancreatic cancer units or centres that have a core multidisciplinary team (MDT) and an extended team of health professionals detailed here. Such units are far from universal in European countries. To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 34238640     DOI: 10.1016/j.ctrv.2021.102208

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  1 in total

1.  The Effect of Comfort Care on Postoperative Quality of Life, Psychological Status, and Satisfaction of Pancreatic Cancer Patients.

Authors:  Yingliang Miao
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-30       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.